- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06009588
Comparison of Self- and Balloon-expandable Valves in Patients With Ascending Aortic Dilation Undergoing Transcatheter Aortic Valve Replacement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Ascending aortic (AA) dilation is a common feature in patients with aortic stenosis (AS), especially in those with bicuspid aortic valve (BAV). For patients undergoing surgical aortic valve replacement (SAVR), current guidelines recommend concomitant aortic repair or replacement if the diameter of AA exceeds 45mm to avoid aortic dissection or rupture.
Transcatheter aortic valve replacement (TAVR) has profoundly changed the clinical management of AS patients who cannot tolerate SAVR. For patients who are candidates for TAVR, simultaneous repair of a dilated AA can be technically difficult. The safety and feasibility of the procedure and the fate of AA after the procedure in these patients remain unclear. Moreover, there are limited data comparing the performance of self-expandable valves versus balloon-expandable valves in these patients. The aim of the present study is to evaluate the impact of type of transcatheter heart valves on intra-procedural device success and post-procedural AA progression in patients with dilated AA (≥45mm) undergoing TAVR.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100037
- National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Severe aortic stenosis;
- Transfemoral access;
- Preoperative aortic CT suggesting maximum ascending aortic diameter ≥45mm and <55mm;
- Anticipated life expectancy >1 year;
- Age ≥ 65 years.
Exclusion Criteria:
- Dominant aortic regurgitation,;
- A history of SAVR or TAVR;
- A history of aortic surgery;
- Emergent TAVR.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Self-expandable valve group
Patients using self-expandable valves
|
patients undergoing TAVR use either self-expandable valves or balloon-expandable valves
|
Experimental: Balloon-expandable valve group
Patients using balloon-expandable valves
|
patients undergoing TAVR use either self-expandable valves or balloon-expandable valves
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
30-day all-cause mortality
Time Frame: 30 days after TAVR procedure
|
all-cause mortality within 30 days after TAVR procedure
|
30 days after TAVR procedure
|
30-day adverse aortic events
Time Frame: 30 days after TAVR procedure
|
aortic death, aortic dissection, or aortic rupture
|
30 days after TAVR procedure
|
The rate of device success
Time Frame: 30 days
|
Device success is defined as following:
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year all-cause mortality
Time Frame: 1 year after TAVR procedure
|
all-cause mortality
|
1 year after TAVR procedure
|
1-year cardiovascular mortality
Time Frame: 1 year after TAVR procedure
|
Related to heart failure, cardiogenic shock, bioprosthetic valve dysfunction, myocardial infarction, stroke, thromboembolism, bleeding, tamponade, vascular complication, arrhythmia or conduction system disturbances, cardiovascular infection (e.g.
mediastinitis, endocarditis), or other clear cardiovascular cause
|
1 year after TAVR procedure
|
1-year adverse aortic events
Time Frame: 1 year after TAVR procedure
|
aortic death, aortic dissection, or aortic rupture
|
1 year after TAVR procedure
|
Ascending aortic diameter expansion rate ≥3mm/year
Time Frame: 1 year after TAVR procedure
|
Expansion rate was calculated as the change of ascending aortic diameters (before the procedure and at the latest follow-up) divided by the follow-up period.
|
1 year after TAVR procedure
|
Hospitalization (or re-hospitalization)
Time Frame: 1 year after TAVR procedure
|
Any admission after the index hospitalization or study enrolment to an inpatient unit or hospital ward for ≥24 h, including an emergency department stay. Hospitalizations planned for pre-existing conditions are excluded unless there is worsening of the baseline condition. Visits to urgent care centres or emergency departments <24 h may also be included if substantive intensification of therapy changes (e.g. heart failure episodes) are enacted (e.g. intravenous diuretics, significant increases in drug therapy dosages or addition of new pharmacotherapy agents) |
1 year after TAVR procedure
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiangbin Pan, MD, Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Saint Petersburg State University, RussiaNot yet recruitingIschemic Heart Disease | Mitral Insufficiency | Aortic Stenosis, Severe | Mitral Stenosis | Aortic Insufficiency | Ascending Aortic Aneurysm | Mitral Stenosis With Insufficiency | Tricuspid InsufficiencyRussian Federation
-
Pan XiangbinRecruiting
Clinical Trials on type of transcatheter heart valves
-
Abbott Medical DevicesCompletedAortic Valve Stenosis | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral Valve Stenosis | Mitral Valve Regurgitation | Aortic Valve Incompetence | Mitral Valve Incompetence | Aortic Valve RegurgitationUnited States
-
corlifeUniversitaire Ziekenhuizen KU Leuven; Hannover Medical School; Hospital Clinic... and other collaboratorsCompletedAortic Replacement Using Individualised Regenerative Allografts - ARISE (the "Surveillance") (ARISE)Heart Valve DiseaseGermany, Switzerland, Belgium, Italy, Netherlands, Spain, United Kingdom
-
Nanjing First Hospital, Nanjing Medical UniversityRecruiting
-
Abbott Medical DevicesActive, not recruitingTricuspid Valve RegurgitationSpain, Denmark, Switzerland, Germany, Netherlands, Italy, Austria, Portugal
-
Edwards LifesciencesRecruiting
-
The Society of Thoracic SurgeonsAmerican College of CardiologyCompletedSevere Symptomatic Aortic Stenosis
-
Heidelberg UniversityUnknown
-
Federico II UniversityRecruiting
-
University Hospital, MontpellierCompletedHemodynamic Instability | Coronary SyndromeFrance
-
Edwards LifesciencesCompletedAortic Valve DiseaseUnited Kingdom, France, Germany, Italy, Canada